Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors
Crossref DOI link: https://doi.org/10.1007/s00280-015-2845-1
Published Online: 2015-10-20
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Fox, Elizabeth
Widemann, Brigitte C.
Pastakia, Devang
Chen, Clara C.
Yang, Sherry X.
Cole, Diane
Balis, Frank M.
Text and Data Mining valid from 2015-10-20